Clinical TrialsThe completion of enrollment in the Phase 2a study for GRI-0621 in idiopathic pulmonary fibrosis patients marks a positive milestone for GRI Bio.
Financial StabilityGRI Bio's solid financial foundation is supported by sufficient cash reserves into 2026, bolstered by $5 million raised in the current quarter.
Safety ProfileGRI-0621 is well-tolerated, with no meaningful changes in HDL, LDL, or triglycerides, showcasing a favorable safety profile and de-risking future data readouts.